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Protease inhibitors represent some of the most potent agents available for therapeutic strategies designed
to inhibit human immunodeficiency virus type 1 (HIV-1) replication. Under certain circumstances the virus
develops resistance to the inhibitor, thereby negating the benefits of this therapy. We have carried out
selections for high-level resistance to each of three protease inhibitors (indinavir, ritonavir, and saquinavir) in
cell culture. Mutations accumulated over most of the course of the increasing selective pressure. There was
significant overlap in the identity of the mutations selected with the different inhibitors, and this gave rise to
high levels of cross-resistance. Virus particles from the resistant variants all showed defects in processing at
the NC/p1 protease cleavage site in Gag. Selections with pairs of inhibitors yielded similar patterns of
resistance mutations. A virus that could replicate at near-toxic levels of the three protease inhibitors combined
was selected. The pro sequence of this virus was similar to that of the viruses that had been selected for
high-level resistance to each of the drugs singly. Finally, a molecular clone carrying the eight most common
resistance mutations seen in these selections was characterized. The sequence of this virus was relatively stable
during selection for revertants in spite of displaying poor processing at the NC/p1 site and having significantly
reduced fitness. These results reveal patterns of drug resistance that extend to near the limits of attainable
selective pressure with these inhibitors and confirm the patterns of cross-resistance for these three inhibitors
and the attenuation of virion protein processing and fitness that accompanies high-level resistance.
The evolution of resistance to human immunodeficiency vi-
rus type 1 (HIV-1) protease inhibitors (PI) represents a signif-
icant limitation to antiviral therapy. Resistance to protease
inhibitors was initially shown by selection experiments carried
out in vitro to be attributable to well-defined mutations in the
pro gene encoding the viral protease. To a large extent, resis-
tance mutations that were identified in the selections in cell
culture overlap the mutations seen in subjects failing therapy
(reviewed in reference 71).
Therapeutic doses of PI are given at near-toxic levels to
provide the maximal inhibitory effect. Even under these cir-
cumstances the number of resistance mutations present at the
first time of apparent virus rebound is relatively small, al-
though more mutations can accumulate over time under this
constant level of selective pressure (11, 13, 22, 45, 50, 62, 74).
Thus, the potential limit of selective pressure for these drugs
has likely not been explored.
One strategy for achieving higher selective pressure has
been to use two PI together. This approach has three potential
advantages. First, nonoverlapping toxicities allow for a higher
combined inhibitory effect without the associated higher tox-
icity. Second, one PI can enhance the pharmacokinetic prop-
erties of a second inhibitor to provide a higher and more stable
drug level between doses (12, 36, 44). Third, PI that are able to
select for unique resistance mutations could be paired. These
potential advantages have been explored in a number of clin-
ical trials (for examples, see references 8, 10, 16, 17, 23–28, 32,
33, 38, 41, 49, 54, 57, 58, 72, and 78). Some information is
available about resistance profiles selected by pairs of PI from
PI-naïve subjects failing such therapy (41), although in most
cases these subjects had previously failed therapy that included
a single PI (16, 25, 32, 38).
Subjects treated with potent PI, either singly or multiply, for
an extended period of time can accumulate many mutations.
There is an association between the accumulation of multiple
mutations and the acquisition of cross-resistance to other PI
(11, 13, 15, 19, 20, 29, 35, 45, 46, 55, 64, 73, 76). The functional
significance of this cross-resistance is seen in the association
between therapy failure with the presence of resistance muta-
tions in the protease or with direct measurements of pheno-
typic cross-resistance (2, 4, 5, 7, 10, 15–17, 19, 21, 25, 28, 32, 34,
38–40, 47–49, 51, 54, 60, 65, 67, 75, 78).
We have explored the question of high-level selection by
using a cell culture-based system to select for high-level resis-
tance to three clinically approved PI (indinavir [IDV], saquina-
vir [SQV], and ritonavir[RTV]) either separately or in pairs. In
addition, we have taken resistant virus pools and selected for
resistance to all three inhibitors together at near-toxic drug
levels. Most of these selections showed a similar pattern of
accumulation of mutations with two active-site mutations at
codon positions 82 and 84 in the pro gene and with a partially
overlapping set of non-active-site mutations. Finally, we have
created an infectious molecular clone carrying many of these
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mutations and generated virus from this clone to examine the
stability of these mutations and their effects on viral fitness.
These studies explore the limits of resistance that can be se-
lected by these widely used protease inhibitors.
MATERIALS AND METHODS
PI. SQV was provided by Ian Duncan, Roche Research Center, RTV was
provided by Dale Kempf, Abbott Laboratories, and IDV was provided by Emilio
Emini, Merck Research Laboratories.
Cell lines. CEMx174 cells were maintained in RPMI 1640 medium with 10%
fetal calf serum and penicillin-streptomycin. HeLa-CD4-LTR--gal (MAGI)
cells (37) were grown in Dulbecco’s modified Eagle-H medium supplemented
with 10% fetal calf serum, 0.1 mg of active G418 per ml, and 0.1 mg of hygro-
mycin B per ml. HeLa and 293T cells were maintained in Dulbecco’s modified
Eagle-H medium supplemented with 10% fetal calf serum and penicillin-strep-
tomycin. CEMx174 and MAGI cell lines were obtained from the National Insti-
tutes of Health AIDS Research and Reference Reagent Program.
Selections. An aliquot of 3  106 CEMx174 cells was incubated at 37°C for 2
to 3 h with 250 l of a virus stock generated from the HIV-1 infectious molecular
clone NL4-3 (1). The culture volume was then brought to 10 ml with medium.
Each flask received one of the following inhibitors at the indicated concentra-
tion: 8 nM SQV, 45 nM RTV, or 24 nM IDV. The multiple-PI flasks received one
of the following concentration combinations: 6 nM SQV–22.5 nM RTV, 30 nM
RTV–16 nM IDV, or 16 nM IDV–8 nM SQV. The selection data with SQV have
been described in part previously (74) and are included here for comparison.
After 48 h and daily thereafter, the cells were pelleted by centrifugation and 10
ml of fresh medium and inhibitors were added. When the culture had undergone
extensive cytopathic effect (CPE), the supernatant medium and the cells were
harvested separately and stored at 70°C. The virus-containing supernatant was
used to start the next round of infection, and after four rounds at the initial
concentration, the inhibitor concentration was increased 1.5-fold at each subse-
quent round of virus growth as described in Results. The level of resistance (50%
inhibitory concentration [IC50]) of the single inhibitor-selected virus pools was
determined by a modified MAGI cell assay (37), as described previously (74), in
which the protease inhibitor is added to productively infected cells and the titers
of supernatant virus made in the presence of the inhibitor are determined for
infectious virus in the MAGI cell assay. For selection with pairs of inhibitors, the
same initial inhibitor concentration cited above was used in the first four rounds
of selection, with each inhibitor increased 1.5-fold at each subsequent passage.
After one of the inhibitors reached a concentration of 5 M, both inhibitors in
the culture were fixed at 5 M for a final 10 passages. To select in the presence
of all three inhibitors, the third inhibitor was added at 5 M to each of the three
cultures that had been selected to 5 M each with the pairs of inhibitors and
passaged 10 times with each of the three inhibitors present at 5 M. The three
cultures that had been passaged with the three inhibitors were pooled, and the
concentrations of the inhibitors were raised 1.5-fold until the concentration of
each inhibitor was 17 M. Attempts to use higher inhibitor concentrations
resulted in cell toxicity.
DNA preparation and amplification of the protease-encoding region. Total
cellular DNA was isolated from infected cell pellets by using the QIAamp blood
kit (Qiagen). The protease-coding domain of viral DNA was amplified by nested
PCR. The PCR conditions are available on request. PCR products were purified
by using QIAquick PCR purification kit (Qiagen) and directly sequenced or
cloned into the pT7Blue vector (Novagen) and sequenced.
Construction of infectious 8mut clone. Cellular DNA from SQV round 27
selection (after selection at 5 M inhibitor for 10 rounds) was used as the source
of a protease gene fragment containing eight mutations (L10I, G48V, I54V,
L63P, A71V, V82T, I84V, L90M). Nested PCR was performed to create an
amplicon spanning the ApaI site in the nucleocapsid (NC)-coding domain to the
5 end of the pol gene, where an RsrII site was introduced. The second-round
PCR product was cloned into the pT7Blue vector, and cloned inserts were
sequenced. The Bsp120I (isoschizomer of ApaI)/RsrII fragment from one clone
that contained the eight protease mutations was ligated into the Bsp120I/RsrII
sites of the pCadNBclBsp clone (S. Pettit, unpublished data). This molecular
clone contains the XbaI (5 of gag) to EcoRV (5 end of reverse transcriptase
[RT]) fragment from HXB within the NL4-3 virus backbone. The resulting
recombinant molecular clone, 8mut, was prepared by use of a Qiagen plasmid
maxikit and transfected into HeLa cells (9). A virus stock was generated by
passage in CEMx174 cells of the supernatant medium from the transfected HeLa
cells.
Virus coculture assay. The 8mut molecular clone virus and a wild-type pro-
tease virus were used in a coculture-growth competition assay experiment to
measure relative fitness. For each of the virus stocks, the titer was determined by
the MAGI cell assay to yield the number of infectious units per milliliter. Ratios
of 10 to 1 and 20 to 1 of infectious 8mut virus to a wild-type protease virus were
used in the competition experiment. For the 10:1 ratio, 2,000 infectious units of
the 8mut virus and 200 infectious units of NL4-3 were used to infect 3  106
CEMx174 cells. Infections were done in a volume of 0.5 ml for 2 h at 37°C. The
cell-virus mixture was centrifuged, and the pellet was resuspended in 1 ml of
phosphate-buffered saline. The cells were centrifuged again, and the pellet was
resuspended in 0.5 ml of 1 trypsin (Sigma) and incubated for 5 min at 37°C.
The cells were centrifuged again and resuspended in medium to make a 10-ml
culture. Every day, the cells were pelleted and the supernatant medium was
aliquoted and frozen at 70°C. The cell pellet was resuspended in 10 ml of fresh
medium and maintained at 37°C. This procedure was repeated until the cultures
showed widespread CPE. An RT assay (6) was performed with the supernatants
to determine the peak of virus production. Viral RNA was extracted from the
collected supernatant samples starting with the day 3 sample for all daily samples
until RT values represented at most 30% of the maximum value. RNA extraction
and PCR amplification were as described by Resch et al. (56). By day 3 under
these conditions, the input viral RNA is diminished, such that the PCR signal
represents newly replicating viral genomes, and stopping the cultures prior to the
maximal RT activity ensures target cell excess during the course of virus spread.
The heteroduplex tracking assay was used to assess the ratio of the variants in the
culture supernatant. Relative fitness was calculated as the change (n-fold) of the
ratio of numbers of mutant virus to numbers of wild-type virus per day (w). To
obtain the change per day, the model in the equation ln (Mt/Wt) 	 ln (w)*t  ln
(M0/W0), where Mt/Wt is the ratio of mutant to wild-type virus at time t and
M0/W0 is the ratio of mutant to wild-type virus at time zero, was employed (30).
This model states that the logarithm of the ratio of mutant to wild type changes
linearly over time and that the slope of the line is the logarithm of the change per
time unit. Linear regression was used to determine the slope.
HTA. Heteroduplex tracking assay (HTA) analysis was performed on some of
the rounds of the selections and on the coculture-growth competition assay
samples. The assay was performed as described by Resch et al. (56). The probe
used to resolve multiple genotypes present in the selections was the multiple-
site-specific probe 6.1. This probe was designed to be sensitive to nucleotide
changes at codon positions 46, 48, 54, 82, 84, and 90, although there is some
sensitivity to changes at other nearby positions. In some cases a subtype A
pro-HTA probe was used, derived from the protease-coding region from a
subtype A primary HIV-1 isolate (9327.5), obtained from John Mascola.
Cleavage site analysis. PCR was used to amplify from total cellular DNA a
585-bp product that included the region of the gag gene encoding the protease
cleavage sites NC/p1 and p1/p6, as well as the protease-coding region. The PCR
products were purified by use of QIAquick PCR purification columns, and the
PCR products were sequenced.
Western blot analysis. Virions from 200 to 500 l of selection culture super-
natants were pelleted in a microcentrifuge at 21,000  g for 1.5 h. The pellets
were resuspended in radioimmunoprecipitation assay buffer in 1/10 volume. For
the 8mut and N432S virions, 10 ml of transfection supernatants were pelleted in
an ultracentrifuge at 70,000  g for 30 min. The virus pellets were resuspended
in 50 l of radioimmunoprecipitation assay (Boehringer Mannheim) buffer. The
samples were mixed with an equal volume of sample buffer (Novex), heated to
85°C for 2 min, and then run in a 16% acrylamide–Tricine gel (Novex). Proteins
in the gel were transferred to a Hybond-P polyvinylidene difluoride membrane
(Amersham Pharmacia Biotech). Viral proteins were detected with a polyclonal
anti-p15 (a gift from Susan Erickson-Viitanen). This was followed by incubation
in the presence of the secondary antibody, anti-rabbit-horseradish peroxidase
(Promega). Finally, the blot was incubated for 5 min with ECL Plus (Amersham
Pharmacia Biotech) detection reagents and then placed on film for visualization.
This p15 antibody appears to be specific for NC, since its reactivity is identical to
an anti-NC antibody (data not shown). An N432S mutant of the NC-p1 process-
ing site, which fails to process at the NC-p1 site (53), was used as a marker for
the NC-p1 intermediate. In a control experiment we showed that the use of the
anti-p15 antibody gave a dose response in signal over a range of a 30-fold dilution
of the target proteins (NC and NC-p1) and that the apparent ratio of NC-p1 to
NC was maintained over this range of signal.
Nucleotide sequence accession numbers. The DNA sequences determined in
this study have been deposited in the GenBank nucleotide sequence database
under accession no. AY203611 to AY203726.
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RESULTS
Selection for high-level resistance in vitro. We selected for
high-level resistance to each of three HIV-1 protease inhibitors
(indinavir, ritonavir, and saquinavir) to evaluate the potential
of each drug to select for mutations that would confer high-
level resistance and to determine the extent to which these
mutations would overlap. Selections were done with each of
the inhibitors starting with concentrations in the low nanomo-
lar range and escalating inhibitor concentration by a factor of
1.5 with each subsequent virus passage. When the inhibitor
concentration reached 5 M, the culture was passaged 10
times to enhance replication rates, and then it was increased to
10 M for 10 passages and then to 15 M for 10 passages. No
cell toxicity was observed at the highest inhibitor concentration
used. The amount of time for each passage (i.e., from the time
of infection to massive CPE) for each of the inhibitors is shown
in Fig. 1. The average time required for the virus to spread
through the culture was 4 to 6 days per passage for each of the
selections, although several of the passages took longer than 10
days (Fig. 1).
HTA analysis after selection in vitro for high-level resis-
tance. Substitution mutations in the protease-coding domain
were examined at various points in the selection protocol by
using two approaches. First, an estimate of total heterogeneity
was made by using an HTA to display potential multiple ge-
notypes (Fig. 2). In this analysis, the labeled HTA probe was
derived from a mutated version of the pro gene designed to
have enhanced sensitivity to substitutions at positions 46, 48,
54, 82, 84, and 90, although other nearby substitutions can also
affect the migration of the probe (56). The HTA conveniently
shows the appearance of new genotypes when assessing a large
number of samples and gives accurate quantitation of the rel-
ative abundance of multiple species, including minor variants
representing as little as 3 to 5% of the population (56). In this
way the HTA analysis can complement and guide the sequence
analysis.
HTA analysis of the IDV selection revealed no variants with
round 1 and 4 samples. Multiple variants were seen at rounds
10, 13, and 16, followed by a homogeneous single population
through the rest of the time points, with a small shift upwards
in the last sample. With the RTV selection, no new variants
were detected in the round 1 or 4 sample, but a doublet that
persisted from round 10 to round 15 was seen. By round 24,
there was a single band, and in rounds 34 and 44 a single band
that shifted slightly higher was apparent. The SQV selection
showed a new variant at round 4 and two different pairs of
doublets appearing during rounds 15 through 18, followed by a
final shift at round 27. This HTA analysis is able to detect only
a subset of the resistance-relevant mutations, although the
ones that are detected are important for the selecting drugs.
These results show that the accumulation of mutations de-
tected by this HTA probe occurred at specific times during the
period of selection. In several cases a variant was stable for
FIG. 1. Time to extensive CPE during PI selections with increasing
inhibitor concentration. Virus generated from the NL4-3 molecular
clone was passaged in the presence of increasing inhibitor concentra-
tion either with a single inhibitor or with multiple inhibitors as de-
scribed in the text. The period of time (in days) until the virus-infected
culture displayed maximal CPE (massive syncytia) was recorded and is
shown as a filled circle for each passage.
FIG. 2. HTA analysis of the pro gene during PI selection. PCR products representing most of protease coding domain were generated as
described by Resch et al. (56). The PCR product was annealed to the 6.1 HTA probe (56), and the heteroduplexes were assessed by native
polyacrylamide gel electrophoresis. The inhibitor used in the selection is shown above the gel, and the round of selection analyzed is shown at the
bottom of each lane. The bracket labeled ht indicates the position in the gel of the heteroduplexes formed between the labeled probe and the
unlabeled PCR product. The position labeled hm represents the probe homoduplex. The inhibitor concentration at each round of passage is shown
in Table 1.
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many rounds of selection, and in two cases (RTV and SQV)
the extensive passage at a 5 M drug concentration reduced
the apparent complexity of the culture from two species to one.
Sequence analysis after selection in vitro for high-level re-
sistance. We next carried out sequence analysis of the viral
genome either by direct sequencing of a PCR product span-
ning the protease-coding domain or by sequencing individual
molecular clones derived from the PCR product. In some
cases, the sequence of the clone was also linked to the migra-
tion of the band in the HTA analysis. Each of the selections
showed a similar pattern of increasing numbers of mutations
after selection with increasing inhibitor concentration (Table
1). Selection with SQV resulted in the early appearance of
mutations at positions 48, 71, and 84, followed by the addition
of a mutation at position 90 by round 15. The doublet that was
apparent in the HTA analysis at round 17 (Fig. 2) represented
the addition of a mutation at position 54. Selection at the
highest drug concentrations resulted in the addition of a V82T
substitution and mutations at positions 10, 63, 73, and 77. The
mutation at position 77 coincided with a reversion at position
71 back to the parental sequence.
Selection with RTV showed a similar pattern of mutations
over time, although in this case a mutation at position 82
appeared early and a mutation at position 84 appeared late.
The early appearance of mutations at positions 82, 54, 63, and
46 is consistent with the ordered appearance of mutations that
occurs in subjects failing RTV therapy (22, 45). The mixture of
species present at round 12 (Fig. 2) represented the presence
or absence of a mutation at position 46, although other sites
not detected by the HTA probe were also incompletely fixed at
that point (i.e., 34 and 63). Overall, mutations became fixed
during the selection and were not lost.
Selection with IDV initially resulted in a series of mutations
that were similar to those present in the RTV culture (V82A,
I54V, L63P). However, the HTA analysis revealed a period of
instability followed by apparent stability. Sequence analysis
revealed that the mixture present at round 13 (Fig. 2) included
the transient appearance of the 54-63-82 constellation of mu-
tations with either M46I or G48V and the appearance of a new
species consisting of M46I, I54V, L63P, A71V, and I84A (the
latter substitution requiring two nucleotide changes). The 84A-
containing genome persisted through the remaining selection
period, with L10I being added as the only obvious resistance-
associated mutation.
Viral sequences recovered after growth in the presence of
the highest inhibitor concentrations had between six and nine
mutations within the protease-coding domain that are well
recognized as being associated with resistance. There was sig-
nificant overlap in the mutations that were seen, especially at
the higher levels of selection. In each case, approximately 50%
of the mutations seen after selection to 15 M with any one
inhibitor were shared among the viral genomes present in
another selection, with mutations at positions 10, 46, 54, 63, 82,
and 84 appearing in at least two of the selected cultures. One
of the two active-site mutations, at positions 82 and 84, ap-
peared early in each of the selections. Mutations at both of
these positions played a role in all three of the selections,
although the mutations were added in distinct ways for each of
the three selections. The active-site mutations appear to influ-
ence at least some of the non-active-site mutations, with L63P
appearing with or closely after a mutation at position 82, and
A71V in two of three cases appearing with a mutation at
position 84.
Evolution of drug susceptibility. Virus pools selected to var-
ious levels of resistance were tested for their susceptibility to
the inhibitor used in the selection and to the other two PI. Loss
in susceptibility (i.e., an increase in the IC50) to the selecting
inhibitor after selection for growth in the presence of 15 M
inhibitor was approximately 3,000-fold for SQV, 1,000-fold for
RTV, and 250-fold for IDV (Fig. 3). As expected, there was an
increase in the level of resistance with increasing selective
pressure.
TABLE 1. Accumulation of mutations in inhibitor-treated virus
pools
PI and round no.
(PI concn in M)a
Mutation observed at indicated drug resistance-associated


























4 (0.016) V V V
10 (0.188) V V V
15 (1.86) V V V L/M
17 (4.2) V V V V M
17-ub V V V V M
17-lb V V V M
18 (5)b V V V S V M
18 (5)b V V V S V M
27 (5)c I V V P V T V M
37 (10) I V V P S I T V M
47 (15) I V V P S I T V M
RTV
4 (0.06)
10 (0.687) V A
12 (1.55) L V P A
12-ub V P A
12-lb L V A
14 (3.48) I L V P A
15 (5)b I V P A
15 (5)b I L V P A
24 (5)c,d I L V P A
34 (10) I L V P A V
44 (15)d,e I I L V P A V
IDV
4 (0.032)
10 (0.365) V P A
13 (1.233) V V P A
13-ub V V P A
13-mb V P A
13-lb I V P V A
16 (4.2) I V P V A
17 (5)b I V P V A
17 (5)b I V P V A
25 (5)c,d I I V P V A
35 (10) I I V P V A
45 (15)d I I V P V A
a ub, upper HTA band; mb, middle HTA band, lb, lower HTA band.
b The products from two PCRs were sequenced for this round of selection.
c At this round, the products from three PCRs per selection were cloned, at
least three clones were sequenced for each PCR product, and the consensus
sequence was determined.
d Presence of p1/p6 P5 position mutation P to L.
e Presence of NC/p1 P2 position mutation A to V. Additional mutations
occurred sporatically at positions 34, 41, 43, and 66. With the exception of E34Q
in the RTV selection, none of these other mutations were fixed.
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There was a similar pattern for cross-resistance in all of the
virus pools. At the highest level of selection, the loss in sus-
ceptibility to the other inhibitors was equivalent to the loss in
susceptibility to the selecting inhibitor, with the exception of
the susceptibility to SQV of the RTV-selected virus, which was
only 200-fold less susceptible to SQV (Fig. 3). As with resis-
tance, cross-resistance increased with increasing selective pres-
sure. Taken together, these results show that the mutations
that confer loss in susceptibility to one inhibitor also confer
loss in susceptibility to the other two inhibitors and that the
high-level selection leads to increased resistance and cross-
resistance.
Effects on protein processing. Amino acid substitutions in
the NC/p1 and p1/p6 processing sites of the Gag precursor
have been detected in vitro and in vivo as compensatory mu-
tations for the protease (3, 14, 18, 42, 77). We examined these
sites in the pools of selected viruses at the levels of 5 and 15
M selection. No changes were seen in these processing sites
in the selection with SQV. However, the NC/p1 site had a
change of alanine to valine at the P2 position of the cleavage
site at the 15 M selection level with RTV, and this pool along
with those selected at both the 5 and the 15 M levels with
IDV had a P5 proline-to-leucine change in the p1/p6 cleavage
site.
Western analysis of pelleted virus particles was performed
from an early time point and from time points adjacent to the
time points that were used for sequence analysis. The virion
proteins were probed with a polyclonal antibody against p15
(the NC-p1-p6 Gag intermediate) in an effort to determine the
extent of processing of the NC-p1 intermediate. As can be seen
in Fig. 4, all of the viruses from the early passages showed a
reduction in the extent of NC/p1 processing. In the case of the
SQV selection, the level of under-processing increased with
the accumulation of mutations in pro and in the absence of
cleavage site mutations. In the RTV selection, there was a
small improvement in the extent of cleavage with the later-
passage virus during the time when the NC-p1 cleavage site
mutation had evolved. The biggest improvement in processing
was seen in the IDV selection, in which the NC-p1 and NC
species appeared equal in abundance in virus from rounds 24
FIG. 3. Drug susceptibility of selected virus pools. Inhibitor-se-
lected virus pools were tested for resistance to the selecting inhibitor
and for cross-resistance to the other two inhibitors. The increase (n-
fold) in IC50 is shown on the ordinate. The level of selection for the
virus pool tested is shown on the abscissa. Drug sensitivity to SQV is
shown in black, that to RTV is shown in stripes, and that to IDV is
shown in white.
FIG. 4. Western analysis of NC/p1 processing in selected pools of
virus. Virus selected with the indicated inhibitor at the indicated round
of selection was pelleted, and the viral proteins were separated in a
polyacrylamide gel under denaturing and reducing conditions. The
proteins were transferred out of the gel onto a membrane, and the
membrane was probed with a polyclonal rabbit antibody to the HIV-1
NC protein. The position of NC/p1 is shown from virus with NC/p1
processing-site mutation N432S (53). The protease active-site muta-
tion D25A is included as a negative control.
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and 44. Surprisingly, this corresponded to the appearance of a
mutation at the P5 position of p1/p6 and also with a change of
active-site mutations from 82A in round 9 to 84A later.
Selection for resistance to multiple PI. We repeated the
selections for resistance with pairs of the three inhibitors
(SQV-RTV, SQV-IDV, RTV-IDV). The inhibitors were used
initially at a ratio that was roughly equivalent to their IC50s,
and the sequential increase in inhibitor concentration was the
same as with the individual inhibitors. At the final round of
selection, each inhibitor was used at 5 M. The time of selec-
tion for each of the passages is summarized in Fig. 1, and
overall these times were similar to those seen with the individ-
ual inhibitors.
Sequence analysis of PCR products spanning the pro gene
revealed a similar pattern for the accumulation of mutations as
seen with the selections with the individual inhibitors (Table
2). Overall, the selection with SQV-RTV was similar to the
selection with SQV, with the initial appearance of 48V and
84V mutations and the late appearance of 82T. Most of the
other resistance-associated mutations were also shared. Nota-
bly, sequence analysis of individual clones from round 27 re-
vealed a mixture of clones having either 82T and 84V or just
84A, with mutations at positions 46 and 48 appearing in both
of these backbones, again suggesting an incompatibility be-
tween a position 82 mutation and 84A.
The overall pattern in the selection with SQV-IDV was very
similar to that seen with the SQV-RTV selection, sharing eight
resistance-associated mutations and showing the early appear-
ance of a position 84 mutation and the later appearance of a
position 82 mutation. In contrast, the selection with RTV-IDV
initially paralleled the selection with RTV, with the early ap-
pearance of a position 82 mutation followed by the appearance
of an 84 mutation. In this culture the G48V mutation also
became fixed. At the highest levels of selection, the two cul-
tures that included SQV shared all eight resistance-associated
mutations and shared seven of eight mutations with the RTV-
IDV culture. Similar trends of association between mutations
at positions 63 and 82 and between positions 71 and 84 were
seen in the IDV-SQV selection but not in the RTV-IDV se-
lection. In the SQV-RTV selection V77I appeared initially,
and only when it reverted did mutations at 63 and 71 appear
together after mutations at both 82 and 84.
In order to detect a limit level of resistance to these inhib-
itors, the three cultures that had been grown in the presence of
pairs of inhibitors were further passaged 10 times in the pres-
ence of all three inhibitors with 5 M of each inhibitor. Se-
quence analysis revealed only small differences between these
cultures and the cultures selected with the pairs of inhibitors
(compare Tables 2 and 3). Finally, these three cultures were
pooled and grown in the presence of increasing inhibitor con-
centration until the total inhibitor concentration was 51 M.
These passages occurred over fairly brief time periods (Fig. 1),
indicating that the virus had attained the ability to replicate in
the presence of these high levels of inhibitor. Sequence anal-
ysis of the pro gene in this culture revealed a total of 10
resistance-associated mutations that remained similar to those
seen with the higher levels of selection with the single- and
dual-inhibitor schemes (Table 3). Higher levels of the pooled
inhibitors resulted in cell toxicity. This constellation of muta-
tions appears to be sufficient to allow virus replication at the
highest levels of inhibitor concentration that can be achieved in
culture with this pooling of inhibitors.
Characterization of a highly resistant clone. The results
described above were obtained with pools of viruses that likely
contained some level of sequence heterogeneity and that had
also been adapted to cell culture growth. We created a molec-
ular clone of HIV-1 containing the eight mutations present at
round 27 of selection with SQV (Table 1). The virus generated
TABLE 2. Accumulation of mutations in multiple
PI-treated virus pools
PI and round no.
(PI concn in M)
Mutation observed at indicated drug resistance-associated



























10 (0.072-0.260) V V
15 (0.563-1.98) V V I A V
16 (1.126-3.96) V V I A V
17 (1.689-5.94)a I I V V P V T V
17 (1.689-5.94)a I I V V P V T V
27 (5.0-5.0)b I I I/L V V P V T V/A
RTV-IDV
4 (0.03-0.016)
10 (0.345-0.183) I V A
14 (1.755-0.93) I I V V A
16 (4.0-2.1) V V V T V
17 (6.0-3.2)a I I V V P V T V
17 (6.0-3.2)a I I V V P V T V
27 (5.0-5.0)b I I I V V P V T V
IDV-SQV
4 (0.008-0.016)
11 (0.093-0.183) V V V
15 (0.473-0.93) V V V
18 (2.13-4.2) V V P V T V
19 (3.2-6.3)a I I V V P V T V
19 (3.2-6.3)a I I V V P V T V
29 (5.0-5.0)b I I V V P V T V
a The products of two PCRs were sequenced for this round of selection.
b At this round, the products from three PCRs per selection were cloned, at
least three clones were sequenced for each PCR product, and the consensus
sequence was determined. Additional mutations not shown: R41I at round 10 of
the RTV-IDV selection. Also, mutations that appeared in at least two of the
clones were M36I of round 27 of the RTV-IDV selection, and M36I, G51R,
G48E, and F53Y of round 27 of the SQV-RTV selection.




Mutation observed at indicated drug resistance-























SQV-RTV-IDV (5-5-5)a I I I V P V A
RTV-IDV-SQV (5-5-5)a I I L V V P V S T V
IDV-SQV-RTV (5-5-5)a I I V V P V S I T V
SQV-RTV-IDV (17-17-17) I I L V V P V S T V
a The supernatants from these three selections were combined to start the next
round of selection. Additional mutations not shown are F53Y for SQV-RTV-
IDV and I66F for RTV-IDV-SQV.
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from this clone, referred to as 8mut, had IC50 increases of
1,400-fold for SQV, 350-fold for RTV, and at least 500-fold for
IDV. These assays were repeated by using the ViroLogic semi-
automated phenotypic sensitivity assay (52). Similar values of
IC50 increase were obtained for SQV (500-fold) and RTV
(150-fold), although a lower value was obtained for IDV with
this alternative assay (53-fold increase). In addition, this assay
was used to detect cross-resistance to nelfinavir (29-fold in-
crease in the IC50) and to a lesser extent to amprenavir (6-fold
increase). Thus, the broad and high level of cross-resistance
can be associated with a specific set of mutations in the protease.
We next examined the stability of the 8mut virus. The virus
was passaged 20 times in the absence of selection and evalu-
ated for reversion of the resistance mutations. HTA analysis
revealed the presence of a mixture of two distinct pro geno-
types by round 10, followed by the slow outgrowth of the
second genotype until it represented approximately one-half of
the virus population by round 20 (Fig. 5A). Bulk sequence
analysis of the PCR product of the protease region through
round 11 showed no changes. From round 12 through round
20, the sequence analysis showed the emergence of a new
species representing a reversion at position 48 to the parental
glycine codon. Thus, overall, this constellation of mutations
appeared to be rather stable during this level of passage in the
absence of drug selection. Analysis of the bulk sequence re-
vealed no mutations within the NC/p1 or p1/p6 cleavage sites.
This lack of evolution of a processing-site mutation was in spite
of the fact that virus from the 8mut showed significantly un-
derprocessed NC/p1 (Fig. 5B).
The growth properties of the 8mut virus were compared
directly with a virus devoid of resistance mutations in a virus
coculture-growth competition assay. The relative ratio of the
coinfecting viruses was monitored daily by using the pro-HTA
(Fig. 5C). The parental wild-type virus rapidly outgrew the
8mut virus, indicating that 8mut is significantly attenuated for
growth. A calculation of the relative fitness value (30) of 8mut
showed that, in the cocultures, the 8mut-to-wild-type ratio
changed 0.5- and 0.6-fold per day in two independent deter-
minations (Fig. 5D). Thus, in spite of its apparent relative
genetic stability with passage 8mut is significantly attenuated
for growth.
DISCUSSION
We initiated these lengthy selections to explore the nature of
high-level resistance to several widely used HIV-1 PI used
either alone or in combination. Initial virologic failure and
resistance to a single PI typically does not lead to the large
number of mutations observed in our selections (11, 13, 22, 31,
45, 50, 62, 74). However, larger numbers of mutations are seen
on occasion, especially after prolonged exposure to drug or
after the use of multiple PI (61, 64, 70, 76). A major difference
between the results of our selections and what is seen with
patients is that we used increasing drug concentrations over a
prolonged period of time while the dosing scheme for patients
remains constant. We do not know how this difference affects
the combinations of mutations seen or whether it may cause
potential differences in the mix of selective pressures for resis-
tance versus fitness.
One significant limitation in cell culture experiments of this
type is that the virus pool in which the selection takes place is
relatively small, introducing the possibility that stochastic ef-
fects may mask a more generalizable observation. There were
several places in the selection course in which multiple geno-
types coexisted over several passages (Fig. 2), demonstrating
the ability of the system to generate multiple viruses with
similar selection coefficients. Also, there was considerable se-
quence overlap in the six independent selections that were
done, suggesting that the mutations observed represent com-
mon pathways to high-level resistance. This is especially true as
many of the mutations likely represent compensatory muta-
tions that affect enzyme activity rather than a direct effect on
inhibitor binding (43, 59, 66).
Several previous studies employing either selection in cell
culture or the analysis of rebound virus in patients have noted
FIG. 5. Analysis of the highly resistant cloned virus 8mut. (A) Stability of the 8mut genotype during passage in culture. Successive rounds of
passage of 8mut in the absence of inhibitor selection were analyzed by HTA of the protease region. The passage number is shown above each lane.
The positions of the 8mut genotype and the V48G reversion to the parental glycine codon are shown, as is the position of the probe homoduplex
(hm). (B) Western analysis of NC/p1 processing of 8mut. Western analysis was carried out as described in the legend to Fig. 4. The positions of
unprocessed Pr55 Gag, NC-p1, and NC are indicated. The virus analyzed in each lane is indicated at the top of the lane. (C) Virus coculture
experiment to measure the fitness of the 8mut virus relative to that of the wild-type virus. Protease HTA was used to distinguish the relative
proportions of the two genotypes on a daily basis. The positions of the 8mut and wild-type (WT) genotypes are shown, as is the position of hm.
The days of culture are indicated above each lane. (D) Fitness calculation for 8mut. The ln (M/W) ratio (open squares) is plotted versus days in
culture, with the slope of the line representing ln (w) (w is the change [n-fold] of the ratio of mutant to wild type per day). Also shown are the
abundance of 8mut (open circle) and that of the parental strain (filled circle). dpi, days postinfection.
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the similarity of mutations and at least partial cross-resistance
to one protease inhibitor with viruses selected for resistance to
other protease inhibitors (13, 45, 73, 76). Our results confirm
and extend those observations. Two of the inhibitors that we
used, RTV and IDV, typically initially select for a position 82
mutation as the first active-site mutation (11, 13, 22, 45, 62, 73),
as was seen in our selections. In contrast, SQV more often
initially selects for position 48 and 90 mutations in vivo (31,
63), although the selection of the active-site I84V mutation can
occur in culture (73, 74) and both position 82 and 84 mutations
can be seen with a subset of subjects with higher drug exposure
(48, 64, 74). Thus, in spite of initial differences in the selected
mutations, the subsequent mutations can have significant over-
lap, and in our selections this included the selection for muta-
tions at two active-site residues, positions 82 and 84. In this way
the evolution of resistance was closely paralleled by the evo-
lution of coresistance.
In examining the pattern of appearance of mutations in
these selections, we noted several distinctive trends. There
were two instances in which the appearance of an I84A muta-
tion was concurrent with the reversion of a position 82 muta-
tion to the wild type. This suggests both that I84A conferred a
higher level of resistance and that its presence was incompat-
ible with a position 82 mutation. The absence of I84A from
clinical isolates does not allow us to evaluate this potential
linkage in sequence databases, and this absence suggests an
important, but undefined, difference in the in vitro and in vivo
selections. Other potential linkages were examined in the da-
tabase (69). In two of our selections there was a switch back to
the wild-type sequence between a position 71 mutation and a
position 77 mutation, suggesting an antagonism between these
positions. However, there is no evidence for such antagonism
in the larger database (N. Hoffman and R. Swanstrom, unpub-
lished observation). Thus, this appears to be a case where a
virus with an altered constellation of mutations replaced a
preexisting dominant strain, rather than a choice between mu-
tually exclusive sequence pathways.
Processing-site mutations associated with resistance are seen
at the processing sites flanking p1 (NC/p1 and p1/p6) (3, 18, 42,
77) but largely not at other sites in Gag, Pro, or Pol (14). When
we examined the extent of processing at NC/p1 we found that
this site was significantly underprocessed in budded virions
isolated from a wide range of points in the selection scheme,
suggesting that attenuation of cleavage at this site is a common
feature of viruses with 82-84 mutations (Fig. 4). The NC/p1
position P2 alanine-to-valine mutation appeared late and only
in the RTV selection and was associated with a slight apparent
improvement in the extent of processing. This was the only
selection of the single-drug selections that maintained a V82A
mutation in the protease, consistent with the idea that NC/p1
processing site mutations are more strongly selected by posi-
tion 82 mutations (3). An improvement in the extent of NC/p1
processing occurred in the IDV selection over a period of time
when 84A was replacing 82A, and there was no processing-site
mutation in the SQV selection in cases where an 84 mutation
appeared first. We also observed p1/p6 mutations at P5 (P to
L) but not the more common P1 L to F (18, 77). We did not
observe a build-up of a p15 (NC-p1-p6) intermediate and have
been unable to assess the impact of this mutation. Bally et al.
(3) have reported an association between this P5 mutation
and a protease position 84 mutation in treated subjects, an
association that was somewhat consistent with our studies (Ta-
ble 1). Given the persistent attenuation of NC/p1 processing, it
seems likely either that the virus has limited capability to revert
this phenotype or that a high level of underprocessing can be
tolerated.
Overall, the patterns of resistance mutations seen in the
selections with pairs of PI paralleled those seen with the single
inhibitors. In the selections that contained SQV (SQV-RTV
and SQV-IDV), the pattern was more similar to the selection
with SQV alone, suggesting that the selective pressure from
SQV was stronger in these cultures in spite of an initial ad-
justment in inhibitor concentrations to reflect their relative
IC50. In one small study, several PI-naïve subjects who failed
SQV-RTV dual therapy had a wide range of mutations that
included substitutions at positions 48, 82, 84, and 90 (41). In
general, subjects with preexisting PI mutations who fail subse-
quent dual PI therapy retain the preexisting mutations and add
several new mutations (16, 32).
We extended the selection with multiple PI by including all
three inhibitors and increasing the inhibitor concentration to
levels that approached cell toxicity. No new or distinctive mu-
tations appeared, but rather the similar pattern of accumula-
tion of the many familiar mutations was apparent. Since these
selections were initiated with a cloned virus, we could identify
all mutations as new sequence variants that were presumably
selected. This included substitutions at positions 10, 63, 71, 73,
and 77, which are known to be polymorphic in the absence of
PI selection (68). Position 10 (59) and position 63 (43, 66)
mutations are known to serve as compensatory mutations for
deleterious resistance mutations. The fact that these sites are
polymorphic in PI-naïve subjects suggests that protease activity
may be regulated over a specific range rather than the maximal
possible activity.
Finally, we explored the characteristics of virus generated
from a molecular clone that had most of the observed muta-
tions. This virus recapitulated the resistance, cross-resistance,
and protein processing patterns seen with the pools of selected
viruses. In addition, we were able to document a significant
fitness decrease in this virus compared to the wild-type parent.
Several features of this fitness loss were unexpected. Many of
the mutations in this virus are considered compensatory; how-
ever, even their presence was not able to increase replication
rates to anywhere near that of wild type. Also, when this virus
was passaged extensively in culture in the absence of protease
inhibitors it was largely stable. Over 20 passages, we detected
only the loss of the 48V mutation. There are three explanations
for the apparent stability. First, the improved fitness by rever-
sion of other single positions may be sufficiently small not to
allow their outgrowth over the period of time during which the
virus was cultured. Second, it may be that the compensatory
mutations are deleterious alone, as are the resistance muta-
tions, thus, to a certain extent locking the constellation of
mutations into a pattern where all single reversions are less fit,
although this possibility was not tested. Third, this level of
passage in vitro may not provide a sufficient evaluation of
genetic stability (although 20 passages in the presence of in-
hibitor permitted the selection of numerous resistance muta-
tions [Tables 1 and 2]). Distinguishing between these three
possibilities is an important question in understanding the na-
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ture of the interactions between the mutations that occur dur-
ing the evolution of high-level resistance to PI.
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